MedTrace Logo

Identification of Graphic Markers of Neurocognitive Disorders (MG)

NCT05537688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2024-02-23

No results posted yet for this study

Summary

The diagnosis of neurocognitive disorders such as early Alzheimer's disease (AD) or primary progressive aphasia (PPA) is particularly difficult and constantly evolving, often leading to diagnostic erraticity. However, several studies have shown that graphic parameters are affected in people with moderate to severe Alzheimer's disease. The use of new technologies in the study and analysis of the abilities of people with neurodegenerative diseases is increasingly recommended. The use of a digital tablet with a stylus makes it possible to objectivize the kinematic parameters of writing (pressure, inclination, speed, jerk, time of writing task) and thus would allow a low-cost diffusion of this technology in particular by including it in already existing screening batteries.

The overall objective of the project is to characterize and compare the graphical markers of a writing task, either language-based (writing words, non-words, sentences) or non-language-based (drawing shapes), in patients with PPA, early-stage Alzheimer's disease (i.e., at the stage of minor neurocognitive disorders and major neurocognitive disorders at the beginning of the disease), and in people with no cognitive disorders.

Conditions

  • Alzheimer Disease
  • Primary Progressive Aphasia
  • Neurocognitive Disorders

Interventions

BEHAVIORAL

Identification of Graphic Markers

The study consists of a single physical visit to the research team's site. Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires. Participants will be evaluated by the principal investigator or his or her representatives from the research team.

Sponsors & Collaborators

  • Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal

    lead OTHER_GOV

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-27
Primary Completion
2023-06-27
Completion
2023-08-27

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05537688 on ClinicalTrials.gov